Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus Bevacizumab in Recurrent Glioblastoma
NCT01632228Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2012
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of onartuzumab in glioblastoma (GBM), sponsored by Roche. Started Jun 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01632228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632228.